Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-06-29Clinical Trial Update: The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia [Phase 4]
A Phase 4 trial evaluated the effects of eszopiclone and escitalopram (Lexapro) on prefrontal glutamate and GABA in adults with depression w…
-
FDA approval · 2012-06-26FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical’s supplemental application for venlafaxine hydrochloride, a generic product. The approval relates to the sta…
-
FDA approval · 2012-06-12FDA Approved: ESCITALOPRAM OXALATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original ANDA for escitalopram oxalate, a generic version of the antidepressant, for treating major dep…
-
CLINICAL_TRIALS trial_result · 2012-05-09Clinical Trial Update: Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) [Phase 4]
Phase 4 trial update evaluating cognitive-behavioral therapy combined with escitalopram for Generalized Anxiety Disorder.
-
CLINICAL_TRIALS trial_result · 2012-05-07Clinical Trial Update: Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain [NA]
This completed clinical trial assessed whether stress-reduction interventions affect brain function and structure in individuals with Genera…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2012-05-03FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) by Viatris Specialty LLC.
-
FDA approval · 2012-05-03FDA Approved: ESCITALOPRAM — Original Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical's original application for escitalopram oxalate, a generic version of the antidepressant escitalopram.
-
FDA approval · 2012-05-02FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride (Vertical Pharmaceuticals, LLC) to update the product labeling und…
-
CLINICAL_TRIALS trial_result · 2012-05-01Clinical Trial Update: Efficacy of Treatment for Generalized Anxiety Disorder
A completed clinical trial evaluating the efficacy of a treatment for generalized anxiety disorder.
-
FDA approval · 2012-04-10FDA Approved: PAROXETINE HYDROCHLORIDE — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for paroxetine hydrochloride submitted by Apotex Corp.
-
FDA approval · 2012-04-02FDA Approved: ESCITALOPRAM OXALATE — Original Application (Rising Pharma Holdings, Inc.)
FDA approves an original application for escitalopram oxalate as a generic drug, manufactured by Rising Pharma Holdings, Inc.
-
CLINICAL_TRIALS trial_result · 2012-03-30Clinical Trial Update: Modular Cognitive Behavioral Therapy for the Treatment of Child Anxiety Disorders in Elementary School Settings [Phase 2]
Phase 2 trial update noting the completion of a modular cognitive behavioral therapy program for treating child anxiety disorders in element…
-
FDA approval · 2012-03-14FDA Approved: ESCITALOPRAM OXALATE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original application for a generic escitalopram oxalate product, expanding access to escitalopram …
-
CLINICAL_TRIALS trial_result · 2012-02-22Clinical Trial Update: Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder [Phase 4]
Phase 4 clinical trial evaluating the safety and efficacy of eszopiclone in patients with generalized anxiety disorder, including those with…
-
CLINICAL_TRIALS research · 2011-12-29Clinical Trial Update: Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders
A clinical trial update evaluating generalization paradigm patterns across multiple psychiatric disorders, including major depressive disord…
-
FDA approval · 2011-12-27FDA Approved: PAROXETINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application from Mylan Pharmaceuticals for paroxetine hydrochloride hemihydrate, authorizing a generic version o…
-
FDA approval · 2011-12-15FDA Approved: PAROXETINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Apotex Corp. to manufacture and market paroxetine hydrochloride as a generic antidepressant.
-
FDA approval · 2011-12-08FDA Approved: ALPRAZOLAM — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for alprazolam submitted by Actavis Pharma, Inc., resulting in changes to the product labeling.
-
FDA approval · 2011-11-22FDA Approved: ALPRAZOLAM EXTENDED RELEASE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Alprazolam Extended Release, authorizing an extended-release formulation of alprazolam by Actavi…
-
FDA approval · 2011-10-18FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for buspirone hydrochloride from Mylan Pharmaceuticals Inc. The approval reflects a supplemental…
-
FDA approval · 2011-09-27FDA Approved: ALPRAZOLAM — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for alprazolam (generic) under Par Health USA, LLC.
-
CLINICAL_TRIALS trial_result · 2011-09-09Clinical Trial Update: Virtual Reality as Anxiety Management Tool for Generalized Anxiety Disorder [NA]
A completed clinical trial evaluating the use of virtual reality as an anxiety management tool for generalized anxiety disorder.
-
CLINICAL_TRIALS trial_result · 2011-09-02Clinical Trial Update: PHARMO Institute Seroquel Safety Study
A completed PHARMO Institute safety study evaluating Seroquel (quetiapine) across schizophrenia, major depressive disorder, bipolar disorder…
-
FDA approval · 2011-08-26FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for buspirone hydrochloride from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2011-08-26FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for buspirone hydrochloride from Mylan Pharmaceuticals Inc., allowing a generic version of the anxie…